Source:http://linkedlifedata.com/resource/pubmed/id/16855078
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2006-7-20
|
| pubmed:abstractText |
The oral tyramine pressor test was administered to healthy males during treatment with a selegiline transdermal system (STS; 6 mg/24 h). The tyramine sensitivity factor (TSF) was calculated from the ratio of baseline and on-treatment tyramine pressor doses. The tyramine sensitivity factor value following 9 days of treatment with the selegiline transdermal system was 1.85 +/- 0.10. Extended treatment, 33 days, produced a small, clinically non-meaningful increase in this value. The tyramine sensitivity factor for the selegiline transdermal system was similar to that following treatment with 10 mg/d of oral selegiline capsules but more than 20 times less than observed during tranylcypromine treatment. A larger increase in the tyramine sensitivity factor was observed following extended selegiline transdermal system treatment at a higher dose (12 mg/24 h), which was significantly decreased following coadministration of tyramine capsules with a meal. These results suggest a wide tyramine safety margin for the selegiline transdermal system and provide evidence that the 6-mg/24-h selegiline transdermal system can be administered safely without dietary tyramine restrictions.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0091-2700
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
933-44
|
| pubmed:dateRevised |
2009-7-17
|
| pubmed:meshHeading |
pubmed-meshheading:16855078-Administration, Cutaneous,
pubmed-meshheading:16855078-Administration, Oral,
pubmed-meshheading:16855078-Adolescent,
pubmed-meshheading:16855078-Adult,
pubmed-meshheading:16855078-Blood Pressure,
pubmed-meshheading:16855078-Cross-Over Studies,
pubmed-meshheading:16855078-Dose-Response Relationship, Drug,
pubmed-meshheading:16855078-Food-Drug Interactions,
pubmed-meshheading:16855078-Heart Rate,
pubmed-meshheading:16855078-Humans,
pubmed-meshheading:16855078-Hypertension,
pubmed-meshheading:16855078-Male,
pubmed-meshheading:16855078-Middle Aged,
pubmed-meshheading:16855078-Monoamine Oxidase Inhibitors,
pubmed-meshheading:16855078-Reference Values,
pubmed-meshheading:16855078-Selegiline,
pubmed-meshheading:16855078-Time Factors,
pubmed-meshheading:16855078-Tranylcypromine,
pubmed-meshheading:16855078-Tyramine
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
|
| pubmed:affiliation |
Somerset Pharmaceuticals, Inc, Tampa, Florida, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|